Browse by ▼

Abbott Laboratories

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Low Levels of Retirement Savings May Be Evidence of a Changing Approach to Retirement

    By Toby Bordelon - March 22, 2013 | Tickers: ABT, CVS, BA

    A recent article in the Wall Street Journal regarding retirement caught my attention (Greene, Kelly and Vipal Monga, “Workers Saving Too Little to Retire.” The Wall Street Journal 19 Mar. 2013: A1; http://online.wsj.com/article/SB10001424127887323639604578368823406398606.html). The gist of it is workers don’t have enough to retire comfortably, a situation brought about by a combination of low savings rates, higher life expectancies, and low interest rates more »

  • Legendary Investor Mason Hawkins Bullish on a Range of Bets

    By Meena Krishnamsetty - March 18, 2013 | Tickers: ABT, CNH, LM, MDLZ, MUR

    Mason Hawkins founded Tennessee-based Southeastern Asset Management in 1975. Southeastern manages roughly $32 billion, with locations in Tennessee, London, Singapore, Sydney and Tokyo. For the last 20 years, Southeastern has managed an average annual return of 10.31%, while the S&P 500 has returned 7.81% annually. Hawkins was heavily influenced by Ben Graham's writings on value investing, which continue to guide the investment philosophy of his funds more »

  • My Perfect Divided Portfolio - Summary and Update

    By Karin Hernandez - March 15, 2013 | Tickers: ABT, ABBV, EPD, LMT, MDP, PRE, SXL, WMB

    In December, I started building what I call my Perfect Dividend Portfolio – one company at a time, and analyzing each company using a rating system I developed myself.

    I review the stocks on seven different criteria; I feel that my selection covers the company’s past dividend-paying history, its potential future earnings growth, and the valuation of the company.

    The company must be yielding at least 3.0% annually, it more »

  • The Value of Making Drugs

    By Katherine Wood - February 26, 2013 | Tickers: ABT, ABBV

    Abbott Laboratories (NYSE: ABT) recently completed a spinoff that created the company AbbVie (NYSE: ABBV).  Since this spinoff, both companies have seen a significant rise in the stock price. From the limited data, it is difficult to tell if one company is a better buy over the other, or if the recent trends in the stock price are merely investor excitement. According to Joel Greenblatt, in his book You Can more »

  • Healthcare Giant's Giant Drug

    By Reuben Brewer - February 25, 2013 | Tickers: ABT, JNJ, MRK

    Dow-30 component Johnson & Johnson (NYSE: JNJ) is a giant healthcare company, with exposure to the consumer products, medical devices, and pharmaceuticals arenas. It's a virtual one-stop shop for investors seeking exposure to the healthcare market. However, within the company's drug business, biologic Remicade accounts for a disproportionate share of revenues. It also has a material impact on the company's top line. Investors need to keep an eye more »

  • 5 Big Pharma Stocks With Healthy Dividends

    By Jordo Bivona - February 23, 2013 | Tickers: ABT, LLY, GSK, MRK, PFE

    Over the years, some of the best performing stocks have boasted long histories of paying healthy dividends to their shareholders. One industry where this can certainly hold true is in big pharma. In this article, I will discuss three big pharmaceutical stocks that continue to offer steady dividends, along with the potential for share growth over the short and long-term horizon.

    Merck (NYSE: MRK) offers a number of different healthcare more »

  • Emerging Markets Are A Major Growth Catalyst For This Big Pharma

    By Jordo Bivona - February 22, 2013 | Tickers: ABT, GSK, PFE

    Emerging pharmaceutical markets including China, India, and Russia should help Pfizer (NYSE: PFE) offset declining profits in the United States. Continued investment in branded generics (drug treatments sold by brand-name companies under generic names) and specifically targeting common diseases and conditions by region will certainly help Pfizer reach its earnings estimates (between $56.2 billion and $58.2 billion) for 2013.

    Impact of international sales

    Fourth quarter and 2012 revenues more »

  • The Better Way To Play Drug Makers

    By Bill Edson - February 21, 2013 | Tickers: ABT, LLY, MRK, PFE

    Analysts wonder if other drug companies will follow in the footsteps of Abbott Laboratories (NYSE: ABT) and spinoff different parts of their business. Abbott spun off its research-based pharmaceutical business, AbbVie (ABBV) at the beginning of 2013. This divestiture benefited Abbott’s investors, who saw a positive total return.

    Are there drug companies that are trading at attractive valuations given their potential for reorganization?

    Pfizer Preparing to Break Apart

    Pfizer more »

  • Billionaire Dan Loeb, Third Point Making Moves Last Quarter

    By Meena Krishnamsetty - February 18, 2013 | Tickers: ABT, ABBV, AAPL, ARIA, EA

    In the hedge fund universe, 13F filing season is here, and we’re bringing you up-to-date coverage of this situation. Our research has shown that hedgies’ consensus small-cap stock picks beat the market by 18 percentage points per year (use our market-beating strategy). Last year the most popular large cap stocks among billionaire fund managers outperformed the S&P 500 index by 8 percentage points as well. Dan Loeb is more »

  • Consider These Big Buys by Todd-Veredus Asset Management

    By Aubrey Tabuga - February 14, 2013 | Tickers: ABT, BAC, CSCO, C, INTC

    Todd-Veredus Asset Management (TVAM) is an investment adviser based in Louisville, Kentucky with $3.060 billion worth of assets under management as of Dec. 31, 2012. TVAM’s investment strategy hinges on price to intrinsic value being the most effective way to determine a stock’s true valuation. Its growth investment philosophy is to go for investments that have positive earnings surprises or estimate revisions. Let us look at this more »

  • 3 Reasons This Dividend Aristocrat has a Recession-Proof Yield

    By Jonathan Yates - February 11, 2013 | Tickers: ABT, PBI, SHW, SYY, WAG

    Despite the worst housing market since The Great Depression, Sherwin Williams (NYSE: SHW), the paint maker and chemicals company, increased its dividend annually throughout The Great Recession.  As a “Dividend Aristocrat,” Sherwin Williams has raised its dividend for over 25 consecutive years.  Here are three of the major reasons that Sherwin Williams has a recession-proof dividend.

    *Sherwin Williams' revenue did not collapse like other companies during The Great Recession.  While more »

  • Insiders Bought These Stocks Recently

    By Meena Krishnamsetty - February 8, 2013 | Tickers: ABT, ADT, EA, GD, TGI

    At Insider Monkey, we track insider purchases because we think that they are an effective signal of an insider’s confidence in a company. Since the insider already has an economic connection to the business, economic theory predicts that they should sell shares in order to increase diversification unless they believe strongly that the stock is undervalued. This is why we’re not surprised that on average stocks bought by more »

  • The Expense Of Diabetes: Is It Worth It?

    By Tyler Wofford - February 7, 2013 | Tickers: ABT, LLY, JNJ, MDT, NVO

    With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming. Like most fields there is stiff competition in the industry. I recently wrote a piece explaining why it appears these companies should be good investments. Since then earnings have been released, so let’s see how they stack up now.

    Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO)  are the more »

  • Don’t be Fooled by this Double Digit Dividend Aristocrat

    By Jonathan Yates - February 6, 2013 | Tickers: ABT, PBI, SHW, SYY, WAG

    Pitney Bowes (NYSE: PBI) is a “Dividend Aristocrat,” which means it has increased its dividend payout for 25 consecutive years.  Unfortunately, there are many reasons why long term income investors seeking rising dividends should not expect this business supply company to continue these increases into the future.

    A major factor is that paying the dividend consumes way too much of Pitney Bowes' earnings.  As the table below shows, the dividend more »

  • Hydrocodone Limitations: Which Pharma Is Hurt?

    By Nate Wooley - January 31, 2013 | Tickers: ABT, ACT, ZGNX

    An interesting thing happened Friday, which I think, is flying under the radar. An advisory panel for the U.S. Food and Drug Administration recommended stricter controls on hydrocodone-based painkillers. That would include such powerful drugs as Vicodin, Lortab and Norco as well as many, many others. The drug was first allowed in the U.S. during WWII, and generics have been around for a long time. It's the more »

  • One Pfizer or Two Pfizers?

    By J.B. Eccard - January 27, 2013 | Tickers: ABT, ABBV, PFE

    When is a company too big? When does it make sense to break up a company, like General Electric or Citi, into smaller parts? In most cases, streamlining a corporation means getting rid of ill-fitting pieces, like General Electric did with NBC Universal. Historically, the decisions to break up a company or to sell off individual business units are almost always company-specific. Rarely does a company follow an industry-wide trend more »

  • Investor: San Francisco Now a ‘Target-rich’ Environment for Biotech M&As

    By Gene J. Koprowski - January 24, 2013 | Tickers: ABT, AMGN, CTIC

    The next generation of biotech stars in therapeutics and diagnostics is now poised to emerge from the San Francisco area, and one high-profile investor has taken to calling the city by the bay a “target-rich” environment for new healthcare M&As.

    Three conferences held in San Francisco earlier this month showcased the new talent, including the Biotech Showcase 2013, OneMedForum SF 2013, and the J.P. Morgan 31st Annual Healthcare more »

  • Three Drug Manufacturers Offering The Best Value Today

    By Cagdas Ozcan - January 23, 2013 | Tickers: ABT, JNJ, MRK

    There are various industries which have provided very safe returns throughout history, and drug manufacturing is certainly one of them. It is one of the rare industries providing sleep-at-night investments. There will never be a peak for producing new drugs because illnesses will be on the face of the earth as long as human kind exists. New drugs with the least side effects and higher efficacy are always favored, so more »